Functional evaluation of a novel vitreous substitute using polyethylene glycol sols injected into a foldable capsular vitreous body. Issue 9 (28th January 2013)

• Record Type: Journal Article
• Authors: Chen, Han; Feng, Songfu; Liu, Yaqin; Huang, Zhen; Sun, Xuyuan; Zhou, Lian; Lu, Xiaohe; Gao, Qianying
• Is Part Of: Journal of biomedical materials research. Volume 101A:Issue 9(2013)
• Page Start: 2538
• Page End: 2547
• Publication Date: 2013-01-28
• Subjects: vitreous substitute -- polyethylene glycol -- biocompatibility -- retention time -- cytotoxicity; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.a.34560
• Languages: English
• ISSNs: 1549-3296

Abstract

Abstract : Polyethylene glycol (PEG) is a short‐term (41 days) potential vitreous substitute and is too short for an ideal vitreous substitute. Previously, a foldable capsular vitreous body (FCVB) was designed to mimic vitreous function. The aim of this study is to evaluate whether PEG injected into FCVB can serve as a long‐term vitreous substitute. In vitro study, a concentration of 5% (w/v) PEG sols showed natural‐like mechanical and optical properties in terms of pH, density, light transmittance, refractive index, interfacial tension, viscosity, rheology, and cytotoxicity. Then in vivo tests, 30 rabbits received standard pars plana vitrectomy, of which 12 eyes were implanted with PEG injected into FCVB, nine eyes were injected with PEG sols alone, and nine others were injected with balance salt solution as control. A clinical evaluation of the anterior segment, fundus, and intraocular pressure was measured pre‐ and postoperatively up to 180 days, which showed that FCVBs had good retina supporting function, except for a higher incidence of cataracts. Gross pathology, hematoxylin and eosin, and terminal deoxynucleotidyl transferase dUTP nick end labeling staining analysis also showed that FCVBs had good biocompatibility, and that all quadrants of the capsular wall fitted well with the retina. This study demonstrated that PEG injected into FCVB can serve as a long‐term vitreous substitute and has potential clinical use. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 101A: 2538–2547, 2013.